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Background  
This bulletin communicates changes to the September 2019 version of the MassHealth Drug 
List, including the MassHealth ACPP/MCO Uniform Preferred Drug List, and 
corresponding actions that MassHealth Accountable Care Partnership Plans (ACPPs) and 
Managed Care Organizations (MCOs) must take pursuant to Section 2.6.B.4 of their 
respective ACPP and MCO contracts with MassHealth. The MassHealth Drug List (MHDL) 
can be found online at www.masshealthdruglist.ehs.state.ma.us/MHDL/  
Updates to HCV Preferred Drug Products 
Effective October 1, 2019, MassHealth added Asegua’s authorized generic products, 
ledipasvir/sofosbuvir and sofosbuvir/velpatasvir as preferred products within the 
therapeutic class of Hepatitis C agents.  
Effective October 1, 2019, MassHealth removed brand name Epclusa, Harvoni and Sovaldi 
from the preferred product drug list.  
Within 90 days of the effective date, and no later than January 1, 2020, MassHealth ACPPs 
and MCOs must update their respective drug lists or formularies within the therapeutic 
class of Hepatitis C agents to align their preferred drug policies with the preferred drugs in 
the MHDL. However, MassHealth ACPPs and MCOs must allow any patients who initiated 
therapy prior to the implementation date of the formulary update to complete their course 
of treatment without a change in product. 
The four preferred drugs in the class must be listed with preferred status on MassHealth 
ACPPs’ and MCOs’ respective drug lists and formularies and must not be disadvantaged 
relative to any other Hepatitis C agents, in accordance with MHDL requirements for the 
class.  
As a reminder, all other Hepatitis C medications will require clinical rationale for use of a 
medication other than a preferred product.  
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Updates to HIV Preferred Drug Products 
Effective October 1, 2019, MassHealth added Dovato (dolutegravir/lamivudine), Juluca 
(dolutegravir/rilpivirine), and Triumeq (abacavir/dolutegravir/lamivudine) as preferred 
products within the therapeutic class of antiretroviral/HIV agents, along with Biktarvy 
(bictegravir/emtricitabine/tenofovir alafenamide), Descovy (emtricitabine/tenofovir 
alafenamide), Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide), 
Norvir (ritonavir tablet), and Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide).  
Within 90 days of the effective date, and no later than January 1, 2020, MassHealth ACPPs 
and MCOs must update their respective drug lists or formularies within the therapeutic 
class of Antiretroviral/HIV agents to align their preferred drug policies with the preferred 
drugs in the MHDL. The preferred drugs in the class must be listed with preferred status on 
MassHealth ACPPs’ and MCOs’ respective drug lists and formularies and must not be 
disadvantaged relative to any other antiretroviral/HIV agents, in accordance with MHDL 
requirements for the class.  
MassHealth Website 
This bulletin is available on the MassHealth website at www.mass.gov/masshealth-
provider-bulletins. 
To sign up to receive email alerts when MassHealth issues new bulletins and transmittal 
letters, send a blank email to join-masshealth-provider-pubs@listserv.state.ma.us. No text 
in the body or subject line is needed. 
Questions 
If you have any questions about the information in this bulletin, please contact the 
MassHealth Customer Service Center at (800) 841-2900, email your inquiry to 
providersupport@mahealth.net, or fax your inquiry to (617) 988-8974. 
